Aspirin Use Does Not Reduce Risk of Colorectal Cancer Recurrence
There was no evidence that aspirin use beginning at the onset of chemotherapy affected the risk of recurrence among patients with stage II or III colorectal cancer.
There was no evidence that aspirin use beginning at the onset of chemotherapy affected the risk of recurrence among patients with stage II or III colorectal cancer.
Second-line systemic therapy with regorafenib improves overall survival among patients with hepatocellular carcinoma (HCC).
GEMOX post-surgery adjuvant therapy does not improve relapse-free survival (RFS) among patients with biliary tract cancer.
Phase 2 trials of investigational agents for pancreatic cancer treatment do not usually progress to phase 3.
Bursectomy can be safely performed without increasing the risk of morbidity or mortality among patients with cT3 or cT4 gastric cancer.
The addition of everolimus to paclitaxel did not significantly improve overall response rate, progression-free survival, or overall survival.
For patients with advanced gastric cancer, second-line treatment with ramucirumab is safe and efficacious regardless of age.
Salvage therapy with nivolumab was efficacious among patients with advanced or recurrent gastric or gastroesophageal junction (GEJ) cancer.
Altering chemotherapy during neoadjuvant chemoradiotherapy based on response to induction chemotherapy by PET imaging can improve pathologic complete response.
Among patients with advanced colorectal cancer, greater total physical activity improved progression-free and overall survival.